Topical Corticosteroid Prescribing Patterns following Changes in Drug Benefit Status

Campbell, Chole A.; Cooke, Charmaine; Weerasinghe, Swarna; Sketris, Ingrid; McLean-Veysey, Pam; Skedgel, Chris

doi:10.1345/aph.1c196

Cited by 5 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may be explained by the fact that the portion of the 24 therapeutic classes of the total pharmaceutical expenditure was relatively small (2.1%), weakening the effect, although expenditures decreased for some drugs. These results are consistent with the findings of Soumerai et al, who analyzed data on claims from New Jersey Medicaid patients after the removal of drugs in 12 categories from the reimbursement listing and found that excluded drugs accounted for 7% of total drug use but that the delisting of these drugs did not have a significant negative effect on the total pharmaceutical expenditure [4].…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Effects of delisting nonprescription combination drugs on health insurance expenditures for pharmaceuticals in Korea

et al. 2016

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

“…Campbell et al concluded that prescriptions for a topical corticosteroid combination drug decreased after its exclusion [4] and that the restriction of meperidine eliminated the user of analgesic meperidine [5]. On the other hand, Kreling demonstrated an increase in the total drug expenditure by the restriction of analgesics [6].…”

Section: Introductionmentioning

confidence: 99%

Effects of delisting nonprescription combination drugs on health insurance expenditures for pharmaceuticals in Korea

et al. 2016

View full text Add to dashboard Cite

“…Among the 35 articles that satisfied the inclusion criteria, 11 –47 several general trends were observed. Most studies ( n = 18, 43.9%) had been carried out in one province, British Columbia.…”

Section: Resultsmentioning

confidence: 95%

Impact of Drug Plan Management Policies in Canada: A Systematic Review

et al. 2008

View full text Add to dashboard Cite

Background/objective: In Canada, pharmaceutical expenditures require an increasing proportion of total health care dollars. Drug plan managers use various policies to manage medication use and control costs, but these policies can have unintended consequences. The objective of this systematic review is to evaluate the impact of drug policies on economic, clinical and humanistic (quality of life or satisfaction) outcomes. Methods: Articles in which the primary objective was to evaluate the impact of a drug policy tool or technique in Canada and that measured one or more economic, clinical or humanistic outcomes were considered for inclusion. Studies were excluded if they were based in institutions or not published in peer-reviewed journals. The search process included searching 9 electronic databases, searching the reference lists of identified articles and working papers and contacting drug policy researchers. Studies were assessed for quality and suitability for meta-analysis. We performed a qualitative synthesis of the study design, study sample and outcomes. Results: Thirty-five articles satisfied the inclusion criteria. Most ( n= 25, 71%) determined that drug policies reduced the costs, utilization or both of the studied drug therapy. Only 13 studies (37%) measured the impact of the drug policy on the cost or utilization of medical care, and the impact of the policy was favourable in only 4 of these cases. Six studies (17%) evaluated the impact of the policy on clinical outcomes; none reported a favourable impact. No studies evaluated the impact of the drug policy on humanistic outcomes. Discussion: Although the drug policies in most of the studies included in this systematic review did achieve the desired goal of reducing drug costs, utilization or both, the impact on other outcomes was seldom examined. In the 6 studies in which clinical outcomes were included in the evaluation framework, the impact was inconclusive. Humanistic outcomes have been completely excluded from evaluations to date.

show abstract

“…Another study assessed the impact of the exclusion of selected topical corticosteroid products from the Nova Scotia formulary in 2000, after an evidence-based drug review of this therapeutic class found certain topical corticosteroids did not meet standards for inclusion (Campbell et al, 2003). Not surprisingly, use of certain topical corticosteroid products decreased after this change, as well as associated average costs.…”

Section: Box 4 Evidence Of the Impact Of Formulary Listing On Consumption Patternsmentioning

confidence: 99%

Pharmaceutical Pricing and Reimbursement Policies in Canada

Paris

Docteur²

2006

OECD Health Working Papers

View full text Add to dashboard Cite

This paper describes and assesses pharmaceutical pricing and reimbursement policies in Canada, considering them in the context of the broader policy and market environment in which they operate, and investigating their role in contributing to Canada’s achievements in meeting a range of objectives relating to the pharmaceutical policy. The federal government regulates prices of patented pharmaceutical products with the objective of protecting consumers against excessive prices. Regulation has very likely been responsible for bringing Canada’s prices for patented medicines roughly in line with European comparators. Prices of generic products, which are not regulated, are relatively high although high... Ce document décrit et évalue les politiques de prix et de remboursement des médicaments au Canada, en les situant dans le contexte politique et l’environnement de marché dans lesquels elles s’inscrivent ; et en observant leur rôle dans l’atteinte des objectifs relatifs à la politique pharmaceutique canadienne. Le gouvernement fédéral régule les prix des médicaments brevetés dans le but de protéger les consommateurs de prix excessifs. Cette régulation a très probablement eu pour effet d’amener les prix des médicaments brevetés canadiens au niveau des prix des pays européens auxquels le Canada se compare. Les prix des médicaments génériques, qui ne sont pas régulés, sont relativement élevés malgré une forte pénétration des...pharmaceutical policy, pricing and reimbursement, pharmaceutical market, Canada, Canada, marché pharmaceutique, politique pharmaceutique, prix et remboursement

show abstract

Topical Corticosteroid Prescribing Patterns following Changes in Drug Benefit Status

Abstract: Prescribing of topical corticosteroid combination products in Nova Scotia decreased following the formulary revision. There was an increase in potent topical corticosteroid prescribing. Future study involving evaluation of patient outcomes would be useful.

Cited by 5 publications

References 10 publications

Effects of delisting nonprescription combination drugs on health insurance expenditures for pharmaceuticals in Korea

Effects of delisting nonprescription combination drugs on health insurance expenditures for pharmaceuticals in Korea

Impact of Drug Plan Management Policies in Canada: A Systematic Review

Pharmaceutical Pricing and Reimbursement Policies in Canada

Contact Info

Product

Resources

About